Royalty Pharma plc (RPRX)
↓ Download CSV- Sector Manufacturing
- Incorporated X0
- Fiscal year ends Dec 31
In fiscal 2025, Royalty Pharma plc reported revenue of $2.38B, up 5.1% from the prior year. The company was profitable, with a net margin of 32.4%. It held $19.62B in total assets against $9.91B in total liabilities.
Key ratios (FY2025)
65.6%
Operating margin
32.4%
Net margin
7.9%
Return on equity
+5.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B | — |
| Operating Income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B | $2.62B | $1.36B | — |
| Net Income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M | $2.35B | $1.38B | — |
| EPS (Diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | — | — | — |
| Total Assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B | $12.45B | — | — |
| Total Liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B | $6.31B | — | — |
| Shareholders' Equity | $9.71B | $10.34B | $10.08B | $9.53B | $10.25B | $9.90B | $6.14B | $4.55B | $4.46B |
| Cash & Equivalents | $618.70M | $929.03M | $477.01M | $1.71B | $1.54B | $1.01B | $246.20M | — | — |
| Operating Cash Flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B | $1.67B | $1.62B | — |
| Shares Outstanding | 564.46M | 594.11M | 602.90M | 437.97M | 414.80M | 375.45M | — | — | — |
| Dividends Per Share | — | $0.84 | $0.80 | $0.76 | $0.68 | $0.30 | — | — | — |